Eosinophilia in Asthma Patients Is Protective Against Severe COVID-19 Illness

BACKGROUND: There is a paucity of information on coronavirus disease 2019 (COVID-19) outcomes in asthmatics. OBJECTIVE: To identify risk factors associated with admission and subsequent mortality among COVID-19-infected asthmatics. METHODS: Adults at our institution with a positive polymerase chain reaction for COVID-19 between March 14 and April 27, 2020, were retrospectively identified. Comorbidities, laboratory results, and mortality rates during hospitalization were recorded. RESULTS: In total, 737 of 951 (77.5%) asthma patients with COVID-19 were seen in the emergency department (ED), and 78.8% of these ED patients (581 of 737) were admitted. Individuals with previously measured mean absolute eosinophil counts (AEC) >= 150 cells/mL were less likely to be admitted (odds ratio [OR] [0.46, 95% confidence interval [CI]: 0.21-0.98, P = .04), whereas concomitant heart failure (CHF), chronic kidney disease (CKD), and chronic obstructive pulmonary disease (COPD) were risk factors for admission. Hospitalized patients with asthma with peak hospital-measured AEC >= 150 cells/mL (n = 104) were less likely to die compared with those whose AEC remained <150 cells/mL (n = 213) (mortality rate 9.6% vs 25.8%; OR [0.006, 95% CI: 0.0001-0.64, P = .03). This group had also higher preadmission mean AEC (237 +/- 181 vs 163 +/- 147 cells/mL, P = .001, OR = 2012, 95% CI: 27.3-14,816). The mortality rate in patients with asthma alone (no associated CHF, CKD, COPD, diabetes, or hypertension) was similar to that of patients without asthma or any of these comorbidities. CONCLUSIONS: In asthmatics, pre-existing eosinophilia (AEC >= 150 cells/mu L) was protective from COVID-19-associated admission, and development of eosinophilia (AEC >= 150 cells/mu L) during hospitalization was associated with decreased mortality. Preadmission AEC influenced the AEC trend during hospitalization. Having a Th2-asthma phenotype might be an important predictor for reduced COVID-19 morbidity and mortality that should be further explored in prospective and mechanistic studies. (C) 2020 American Academy of Allergy, Asthma & Immunology